BLOG: Significant and Positive Developments HHSE

New Post Public Reply Private Reply Replies (1) Message Board
speckulater
264
BLOG: Significant and Positive Developments




HHSE Investor's Blog


Wednesday, December 30, 2020

Significant and Positive Developments / Updates for Hannover House (HHSE) and MyFlix


Greetings HHSE Friends & Followers. What a crazy year we had in 2020, but what an exciting year we are facing beginning in just the next few days!

Here's a few updates, including the most critically requested information on our FORM 10 Filing, the S1 Offering and the Launch of the MyFlix Consumer Site & Service.

1). MYFLIX - If we were launching a streaming service with one (1) movie via a self-service "ROKU" Channel, we might have been able to create some momentary shareholder excitement... but we would not be creating a legitimate, sustainable service with repeat customers and a major revenue base. Accordingly, it was not surprising to discover (over the past few weeks of work with our web design supplier) that a major site like MyFlix - with access to over 15,000 titles - requires substantial infrastructure and technical attention for proper operations.

What we do NOT want to do is launch with a skeleton site, or with a site featuring only 1,000 titles. On the other hand, we also do NOT want to launch the site and see an immediate crash from data overload and streaming constrictions. Our plan was to publish the consumer site THIS WEEK (between Christmas & New Years), under the belief that there would be a lot of people at home due to Holidays and Covid. But the site simply is not ready, even with a simplified graphics and tendril model.

Based on the ongoing problems with Covid and the delayed vaccine roll-out, we believe that people will STILL be mostly at home for some time... and that a release of the site in January is far more likely to not encounter technical problems.

2). FORM 10 - As described previously, the "going-forward" business model for HHSE is two fold, consisting of the MyFlix service and the production of higher profile features. The prior model of acquiring and distributing micro-budgeted indie films for DVD release is no longer viable due to the maturation of the home video market away from low-budget, non-star-driven titles (plus, we have discovered that many of those micro-budget producers are delusional nuts - and prone to litigation).

Accordingly, much of the body of the Form 10 Registration concerning operations is focused on MyFlix and not surprisingly, many details of the MyFlix site and supplier partner details are disclosed in the Form 10. With technical issues currently impacting the launch date of MyFlix, we find ourselves facing one of two principal choices: 1). Delay the release of the Form 10 until MyFlix is launched; or 2). Revise the Form 10 to remove non-public details about MyFlix, and release this registration immediately after these edits. We have decided to go for option two, and we have been editing / updating the F10 the past three days so that it's publication will not inadvertently expose MyFlix supplier partners and unique site services. We do not want to self-sabotage MyFlix by revealing the details of the service before it is functionally "live" to consumers.

With respect to Form 10 financial details, we have confirmed that there is no issue regarding our filings being viewed as "stale" under S.E.C. timing requirements. So, we will all enjoy an amazing start to 2021... which is more poetic than launching during a historically notorious year anyway.


3). S1 FILING - The filing of the S1 will be just a few days after the publication of the Form 10, and we have received strong indications from media partners and large investors that the initial block of 50-mm shares at $.03 / share are poised to sell out quickly. The likelihood of the second tranche of shares (50-mm at $.05) being sold will likely depend upon the public market's pricing for shares at that time. The funds raised will be utilized 70% for MyFlix and new operations, and 30% for existing debt management

4). DEBT-TO-EQUITY -
In advance of the Form 10 and S1, HHSE made deals to exchange approx. $500,000 of debt into HHSE restricted stock shares, thus improving the company's balance sheet and addressing creditors with a plan that could show them a significant upside.

5). LEGAL UPDATES -
HHSE participated in a court hearing last week regarding the "Getting Grace" dispute. Months ago, we were informed (by the Company's prior counsel in Pennsylvania) that our settlement terms had been accepted but not documented. After months of delays, HHSE ultimately prevailed in getting the case moved into Arkansas - where the local judiciary has little tolerance for inappropriate and unsupported claims by plaintiffs and their attorneys. Following last week's hearing, HHSE and our new counsel in the matter (Steven M. Kay) have renewed confidence that we will prevail in the dispute (instead of making a "settlement" , and were encouraged by the Judge's attention to a discussion about the appropriateness and applicability of awarding legal fees to Hannover House and other improperly named defendants. A long-term schedule was set, and this was a VERY GOOD day for HHSE. Stay Tuned...

GET READY FOR AN AMAZING 2021~!



http://hannoverhousemovies.blogspot.com/2020/...ments.html




Myflix-Image.jpg




Hannover House Inc. (HHSE) Stock Research Links

HHSE Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Exro Technologies Reveals Quarterly Progress and Financial Insights

Updated Category News Views 362

Exro Technologies Reports First Quarter Results Exro Technologies Inc. (TSX: EXRO), a prominent tech company specializing in power control solutions for electric vehicles and energy storage, has recently announced its financial results for the first quarter of the year. This highlights their ongoing transition from technology validation towards commercial operations and...

Continue Reading
dsm-firmenich Appoints New Leaders to Propel Future Growth

Updated Category News Views 548

dsm-firmenich Welcomes New Executive Committee Members dsm-firmenich is set to usher in a transformative era by strengthening its Executive Committee, as it embarks on a journey to intensify its consumer-centered approach. This restructuring aims to solidify its standing as a top-tier partner in creation and innovation across the nutrition, health, and beauty sectors. The...

Continue Reading
Insight Partners Rolls Out $12.5B for Software Innovation Growth

Updated Category News Views 805

Insight Partners Launches New Funds to Propel Software Innovation Global software investor, Insight Partners, has recently celebrated a significant milestone by announcing the closing of its thirteenth flagship fund alongside a dedicated buyout co-invest fund, collectively known as "Fund XIII". This announcement is particularly special as it coincides with the firm's 30th...

Continue Reading
Acumatica's AI Innovations Transform Business Operations

Updated Category News Views 123

Acumatica's AI Innovations Transform Business Operations During an inspiring keynote at a recent summit, Acumatica showcased its commitment to revolutionizing business operations with an AI-first product strategy. This innovative approach aims to significantly enhance how small and mid-sized businesses operate, addressing the real-world challenges they face. With advanced...

Continue Reading
Microbiological Testing of Water Market Growth Forecasts

Updated Category News Views 101

The Expanding Microbiological Testing of Water Market As the demand for clean and safe water continues to surge, the global microbiological testing of water market is set to experience significant growth, reaching an impressive $2.3 billion by 2027, with a robust compound annual growth rate (CAGR) of 7.4%. The rising consciousness among consumers regarding the importance...

Continue Reading